Doribax (doripenem) is approved for the treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections including pyelonephritis.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
FDA Drug Safety Communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia FDA Statement on recently terminated clinical trial with Doribax (doripenem)[ARCHIVED]
- Dear Healthcare Professional Letter (from Janssen Pharmaceuticals) (PDF - 348KB)
FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections[ARCHIVED]